Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including Mounjaro (for diabetes) and Zepbound (for weight loss). Together, those two products generated $5.4 billion in sales for Eli Lilly last quarter, or 40% of the top line.
Eli Lilly & Co. stock underperforms Friday when compared to competitors
Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and Dow Jones Industrial Average DJIA falling 0.
We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...
Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In an era where financial literacy is increasingly recognized as a crucial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback